Related Experiment Video
Updated: Jul 8, 2026
07:35
Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice
Published on: January 26, 2024
Glucagon and hyperglycaemia in diabetes
1Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St Louis, 660 South Euclid Ave, MO 63110, USA. pcryer@wustl.edu
Clinical Science (London, England : 1979)
|January 17, 2008
Summary
Glucagon significantly raises blood glucose and impairs glucose tolerance over four weeks in mice. This study provides sustained evidence for glucagon
Area of Science:
- Endocrinology
- Metabolism
- Diabetes Research
Background:
- Hyperglycaemia in diabetes is linked to glucagon, but long-term evidence is limited.
- Existing evidence often relies on short-term studies or indirect observations.
Purpose of the Study:
- To investigate the sustained glycaemic effects of prolonged hyperglucagonaemia.
- To provide long-term experimental data on glucagon's role in hyperglycaemia.
Main Methods:
- Infusion of glucagon in mice over a four-week period.
- Monitoring of fasting plasma glucose concentrations.
- Assessment of glucose tolerance.
Main Results:
- Sustained elevation of fasting plasma glucose concentrations.
- Impaired glucose tolerance observed over the four-week study duration.
- Demonstrated a long-term glycaemic effect of hyperglucagonaemia in an animal model.
Conclusions:
- Prolonged elevation of glucagon has a sustained detrimental effect on glucose homeostasis.
- This study supports a significant role for glucagon in the long-term hyperglycaemia of diabetes.
- Further human studies are needed to confirm glucagon's pathological role and explore therapeutic strategies.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...